tiprankstipranks
Trending News
More News >
Sanara MedTech (SMTI)
NASDAQ:SMTI
US Market

Sanara MedTech (SMTI) Earnings Dates, Call Summary & Reports

Compare
33 Followers

Earnings Data

Report Date
May 19, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
-0.51
Last Year’s EPS
-0.21
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 25, 2025
|
% Change Since: -22.81%
|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
Sanara MedTech showcased strong revenue growth and profitability improvements, especially in the Sanara Surgical segment. The company expanded its market presence and strategic partnerships, contributing to positive financial performance. However, increased operating expenses and fourth-quarter net losses, especially in the Tissue Health Plus segment, present challenges. Overall, the sentiment of the call is positive, given the significant achievements and strategic advancements outweighing the financial setbacks.
Company Guidance
In the Sanara MedTech earnings call for the fourth quarter and full year 2024, the company reported a net revenue of $86.7 million for the year, marking a 33% growth compared to the previous year. This was largely driven by a 39% increase in sales of soft tissue products, amounting to $76.1 million, and a 6% rise in bone fusion product sales to $10.5 million. The company achieved a positive adjusted EBITDA of $2.7 million, reflecting a $2.6 million improvement year-over-year. Sanara Surgical segment's adjusted EBITDA rose by 73% to $9.1 million, although this was partially offset by continued investments in the Tissue Health Plus (THP) segment. The company ended the year with $15.9 million in cash and $24.5 million available for future borrowings. Looking forward, Sanara aims to enhance market penetration and surgeon adoption of its products in 2025, alongside launching a pilot program for the THP segment.
Strong Year-Over-Year Revenue Growth
The company generated net revenue of $86.7 million for the full-year 2024, representing growth of 33% year-over-year, driven by strong sales of self-tissue products and bone fusion products.
Positive Adjusted EBITDA
The company achieved positive adjusted EBITDA of $2.7 million in 2024, an increase of $2.6 million compared to 2023, reflecting significant profitability improvements within the Sanara Surgical segment.
Commercial Expansion and Strategic Agreements
Sanara expanded its sales coverage, increased distributor partners to over 350, and entered into strategic agreements with Biomimetic Innovations, securing exclusive rights to innovative products.
Successful Financial Management
Net cash use in operating activities was essentially break-even in 2024, with only $24,000 of cash used, compared to $3.2 million in 2023, and a new debt facility was secured for up to $55 million.
Fourth Quarter Revenue Performance
Fourth quarter net revenue grew 49% year-over-year to $26.3 million, with soft tissue repair products increasing 56% and bone fusion products increasing 8%.
Innovation and Intellectual Property Development
The company submitted 11 provisional patent applications in 2024, covering innovations in antimicrobial technologies and hydrolyzed collagen.
---

Sanara MedTech (SMTI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SMTI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 19, 20252025 (Q1)
-0.51 / -
-0.21
Mar 25, 20252024 (Q4)
-0.12 / -0.18
-0.03-500.00% (-0.15)
Nov 12, 20242024 (Q3)
-0.62 / -0.34
-0.13-161.54% (-0.21)
Aug 12, 20242024 (Q2)
-0.21 / -0.41
-0.22-86.36% (-0.19)
May 13, 20242024 (Q1)
-0.07 / -0.21
-0.14-50.00% (-0.07)
Mar 25, 20242023 (Q4)
-0.13 / -0.03
-0.01-200.00% (-0.02)
Nov 13, 20232023 (Q3)
0.00 / -0.13
-0.1827.78% (+0.05)
Aug 14, 20232023 (Q2)
-0.13 / -0.22
-0.4247.62% (+0.20)
May 15, 20232023 (Q1)
-0.33 / -0.14
-0.4165.85% (+0.27)
Mar 20, 20232022 (Q4)
-0.26 / -0.01
-0.4897.92% (+0.47)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

SMTI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 25, 2025$35.69$31.20-12.58%
Nov 12, 2024$34.60$37.22+7.57%
Aug 12, 2024$27.83$32.04+15.13%
May 13, 2024$31.42$29.28-6.81%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Sanara MedTech (SMTI) report earnings?
Sanara MedTech (SMTI) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
    What is Sanara MedTech (SMTI) earnings time?
    Sanara MedTech (SMTI) earnings time is at May 19, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SMTI EPS forecast?
          SMTI EPS forecast for the fiscal quarter 2025 (Q1) is -0.51.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis